Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTMimplant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met t ...

Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Medical entered into a Share Purchase Agreement to sell 7,936,507 ...

Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.

Vivani Medical announced that it brought in $10 million in equity financing as it progresses its drug delivery technology.

Vivani Medical, Inc. ( (VANI) ) has released its Q2 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its investors.Elevate Your Investing Strategy: Take advantage of ...

Vivani’s emerging pipeline includes NPM-139 (semaglutide implant) which is also under development for chronic weight management.

H.C. Wainwright notes that Vivani Medical (VANI) has announced positive preclinical data for NPM-139, a subdermal semaglutide implant being developed for chronic weight management.

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

Vivani’s NPM-115 and NPM-119 are miniature, six-month, GLP-1 implants in development for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes, respectively.